BridgeMD
New treatment option for Ischemic Stroke, Acute
Official title Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study
ClinicalTrials.gov ID: NCT07043686
What this study is testing
What is Cerebrolysin treatment?
Cerebrolysin treatment is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for ischemic stroke, acute.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study evaluates the effect and safety of Cerebrolysin administered during early rehabilitation in patients with moderate neurological impairment after acute ischemic stroke, conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, UMC Ljubljana.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Being able to perform ARAT test Signed informed consent
- Both sexes, age not specified
- Acute ischemic stroke confirmed by imaging
- NIHSS score 6-12
- No prior stroke or disability (mRS 0 before stroke)
You likely can't join if
- Not being able to perform ARAT test
- Previous stroke or disability (mRS \> 0)
- The patient unable to understand instructions
The study team makes the final eligibility decision.
Where it's taking place
- Ljubljana, Slovenia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ljubljana, Slovenia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.